Fighting Cancer with Selective Immunotherapy
We believe we are at the forefront of next generation therapeutics for treating cancer using selective immunotherapeutic products that are based on gene therapy technology (“selective cancer immunotherapy”).
We are initially focused on developing a treatment for an aggressive type of brain cancer, namely recurrent High Grade Glioma (HGG), which includes Glioblastoma Multiforme (GBM) and anaplastic astrocytomas. Potential future indications may include metastatic cancers including melanoma and colorectal cancer.
Thank you for visiting the Tocagen website and for your interest in learning more about our fight against cancer. This website contains information about our company, technology, products and clinical programs. At Tocagen, we are dedicated to fulfilling our Mission and bringing new hope to patients with advanced cancer.
- Harry Gruber, MD, Chief Executive Officer, Tocagen Inc
Tocagen Featured on CBS News
Please see the Disclaimer Notice regarding this video.